Cleminorexton (ORX750) enters Phase 2a trial for narcolepsy and idiopathic hypersomnia

Central disorders of hypersomnolence (CDH), including Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH), are chronic neurological conditions characterized by severe excessive daytime sleepiness (EDS). NT1 is uniquely marked by cataplexy and a profound loss of orexin (hypocretin) neurons, which are critical for maintaining wakefulness. While current treatments often manage symptoms like EDS, they typically do not address the underlying orexin system dysfunction. Developing therapies that directly modulate the orexin pathway could offer a more targeted and effective approach for these debilitating conditions.

This Phase 2a, randomized, double-blind, placebo-controlled study (CRYSTAL-1) investigates Cleminorexton (ORX750). It is recruiting participants aged 18-65 years with BMI 17-37 kg/m2, diagnosed with Narcolepsy Type 1, Type 2, or Idiopathic Hypersomnia (ICSD-3-TR criteria). Participants must discontinue existing narcolepsy medications. The trial aims to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Cleminorexton (ORX750), alongside its potential efficacy in reducing excessive daytime sleepiness and other associated symptoms.

As of the current date, this is a recruiting Phase 2a clinical trial (NCT06752668), and therefore, no findings or results are available yet. The study's primary objective is to gather initial data on the safety and tolerability profile of Cleminorexton (ORX750) in patients with narcolepsy and idiopathic hypersomnia. Secondary objectives include assessing the drug's impact on excessive daytime sleepiness and other symptoms, but specific efficacy data will only emerge once the study is completed and results are analyzed. > The trial is designed to characterize the drug's pharmacokinetics and pharmacodynamics, which will be crucial for informing future larger-scale studies and potential dose optimization.